BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

  March 10, 2025

   · 

  2 min read
• Press Releases

  Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients

  March 10, 2025

   · 

  9 min read
• Press Releases

  Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

  March 10, 2025

   · 

  3 min read
• Press Releases

  Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer

  March 10, 2025

   · 

  6 min read
• Press Releases

  Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

  March 10, 2025

   · 

  7 min read
• Press Releases

  Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights

  March 10, 2025

   · 

  10 min read
• Press Releases

  OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

  March 10, 2025

   · 

  3 min read
• Press Releases

  Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

  March 10, 2025

   · 

  8 min read
• Press Releases

  Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

  March 10, 2025

   · 

  12 min read
• Press Releases

  Lungpacer Medical Announces Investigational Device Exemption (IDE) for STARI, Phase 2 Feasibility Clinical Trial

  March 10, 2025

   · 

  4 min read